These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12188264)

  • 1. Assessing perfusion and capillary permeability changes induced by a VEGF inhibitor in human tumor xenografts using macromolecular MR imaging contrast media.
    Clément O; Pradel C; Siauve N; Frouin F; Bruneteau G; Kahn E; Frija G; Cuénod CA
    Acad Radiol; 2002 Aug; 9 Suppl 2():S328-9. PubMed ID: 12188264
    [No Abstract]   [Full Text] [Related]  

  • 2. Can a small-molecular gadolinium contrast agent be applied successfully with dynamic MRI to quantitatively define brain tumor microvascular responses to angiogenesis inhibition?
    Brasch RC; Gossmann A; Helbich TH; Kuriyama N; Roberts TP; Shames DM; van Bruggen N; Wendland MF; Israel MA
    Acad Radiol; 2002 Aug; 9 Suppl 2():S326-7. PubMed ID: 12188263
    [No Abstract]   [Full Text] [Related]  

  • 3. Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media.
    Pradel C; Siauve N; Bruneteau G; Clement O; de Bazelaire C; Frouin F; Wedge SR; Tessier JL; Robert PH; Frija G; Cuenod CA
    Magn Reson Imaging; 2003 Oct; 21(8):845-51. PubMed ID: 14599534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor microvascular changes to anti-angiogenic treatment assessed by MR contrast media of different molecular weights.
    Roberts TP; Turetschek K; Preda A; Novikov V; Moeglich M; Shames DM; Brasch RC; Weinmann HJ
    Acad Radiol; 2002 Aug; 9 Suppl 2():S511-3. PubMed ID: 12188324
    [No Abstract]   [Full Text] [Related]  

  • 5. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.
    Fox WD; Higgins B; Maiese KM; Drobnjak M; Cordon-Cardo C; Scher HI; Agus DB
    Clin Cancer Res; 2002 Oct; 8(10):3226-31. PubMed ID: 12374693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor.
    Pham CD; Roberts TP; van Bruggen N; Melnyk O; Mann J; Ferrara N; Cohen RL; Brasch RC
    Cancer Invest; 1998; 16(4):225-30. PubMed ID: 9589031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts.
    Checkley D; Tessier JJ; Wedge SR; Dukes M; Kendrew J; Curry B; Middleton B; Waterton JC
    Magn Reson Imaging; 2003 Jun; 21(5):475-82. PubMed ID: 12878256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of antiangiogenic treatment effects on tumors' microcirculation by Bayesian physiological pharmacokinetic modeling and magnetic resonance imaging.
    Brochot C; Bessoud B; Balvay D; Cuénod CA; Siauve N; Bois FY
    Magn Reson Imaging; 2006 Oct; 24(8):1059-67. PubMed ID: 16997076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
    McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
    J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors.
    Zielke A; Middeke M; Hoffmann S; Colombo-Benkmann M; Barth P; Hassan I; Wunderlich A; Hofbauer LC; Duh QY
    Surgery; 2002 Dec; 132(6):1056-63; discussion 1063. PubMed ID: 12490855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.
    Giavazzi R; Sennino B; Coltrini D; Garofalo A; Dossi R; Ronca R; Tosatti MP; Presta M
    Am J Pathol; 2003 Jun; 162(6):1913-26. PubMed ID: 12759248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody.
    Yuan F; Chen Y; Dellian M; Safabakhsh N; Ferrara N; Jain RK
    Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14765-70. PubMed ID: 8962129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor.
    Gossmann A; Helbich TH; Mesiano S; Shames DM; Wendland MF; Roberts TP; Ferrara N; Jaffe RB; Brasch RC
    Am J Obstet Gynecol; 2000 Oct; 183(4):956-63. PubMed ID: 11035346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts.
    Bhujwalla ZM; Artemov D; Natarajan K; Ackerstaff E; Solaiyappan M
    Neoplasia; 2001; 3(2):143-53. PubMed ID: 11420750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of vascular endothelial growth factor 165 drives peritumor interstitial convection and induces lymphatic drain: magnetic resonance imaging, confocal microscopy, and histological tracking of triple-labeled albumin.
    Dafni H; Israely T; Bhujwalla ZM; Benjamin LE; Neeman M
    Cancer Res; 2002 Nov; 62(22):6731-9. PubMed ID: 12438274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells.
    Levine L; Lucci JA; Pazdrak B; Cheng JZ; Guo YS; Townsend CM; Hellmich MR
    Cancer Res; 2003 Jul; 63(13):3495-502. PubMed ID: 12839933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumour growth and angiogenesis in human glioblastoma xenografts.
    Takano S; Tsuboi K; Matsumura A; Nose T
    Neuro Oncol; 2003 Jan; 5(1):1-7. PubMed ID: 12626127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Permeability to macromolecular contrast media quantified by dynamic MRI correlates with tumor tissue assays of vascular endothelial growth factor (VEGF).
    Cyran CC; Sennino B; Fu Y; Rogut V; Shames DM; Chaopathomkul B; Wendland MF; McDonald DM; Brasch RC; Raatschen HJ
    Eur J Radiol; 2012 May; 81(5):891-6. PubMed ID: 21889860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microvascular permeability of human melanoma xenografts to macromolecules: relationships to tumor volumetric growth rate, tumor angiogenesis, and VEGF expression.
    Graff BA; Bjørnaes I; Rofstad EK
    Microvasc Res; 2001 Mar; 61(2):187-98. PubMed ID: 11254398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo.
    Borgström P; Bourdon MA; Hillan KJ; Sriramarao P; Ferrara N
    Prostate; 1998 Apr; 35(1):1-10. PubMed ID: 9537593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.